Clinical Trial Update: Correlation Between SUV on 68Ga-HBED-CC-PSMA and Gleason Score in Prostate Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated whether the SUV from 68Ga-HBED-CC-PSMA PET imaging correlates with Gleason score in prostate cancer. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 68Ga-HBED-CC-PSMA

Snippet

Sponsor: Sir Mortimer B. Davis - Jewish General Hospital | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED